Targeting Cd276 Autologous Chimeric Antigen Receptor T Cells
CAR
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the CAR cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Cd19 Car T-Cells KK Women's and Children's Hospital | Phase 2 | CCC |
Thiscart19A The First Affiliated Hospital of Soochow University | Phase 1 | CC |
taa05 cell PersonGen BioTherapeutics (Suzhou) Co., Ltd. | N/A | D |
Same molecule, other indications
Targeting Cd276 Autologous Chimeric Antigen Receptor T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →